Approved fibroblast growth factor receptor (FGFR) inhibitors include erdafitinib, pemigatinib,
and futibatinib. We review the most common toxicities associated with FGFR inhibitors and …

Despite recent advances, advanced-stage urothelial carcinoma (aUC) remains incurable,
with 5-year survival rates of approximately 10%. Platinum-based chemotherapy has a major …

Simple Summary The mammalian target of rapamycin (mTOR) pathway promotes cell
growth and metabolism in response to growth factors, nutrients, and cellular energy status …

Fibroblast growth factor receptor (FGFR) tyrosine kinases, which are expressed on the cell
membrane, are involved in a wide range of biological functions such as cell proliferation …

Simple Summary Around 20% of advanced bladder cancer patients carry unfavorable
genetic alterations in the fibroblast growth factor receptor 3 (FGFR3) gene. This review …

Dysregulated fibroblast growth factor receptor (FGFR) signaling is associated with several
cancers, including urothelial carcinoma. Preclinical studies with FGFR inhibitors have shown …

Introduction: Fibroblast growth factor receptor (FGFR)/fibroblast growth factor (FGF) is a
pathway characterized by recurring alterations in cancer. Its dysregulations enhance cancer …

Simple Summary In recent years, there have been several advances in the care of advanced
bladder cancer, highlighted by the addition of immune checkpoint inhibitors to the care of …

Simple Summary The aim of this study was to present and analyze the up-to-date literature
describing the epidemiology, genetics, and histopathology of bladder cancer, as well as the …

Inhibitors of fibroblast growth factor receptor (FGFR) signaling have been investigated in
various human cancer diseases. Recently, the first compounds received FDA approval in …